Author:
Sarantou Sofia,Marinakis Nikolaos M.,Traeger-Synodinos Joanne,Siomou Ekaterini,Ntinopoulos Argyrios,Serbis Anastasios
Abstract
Abstract
Background
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder typified by various combination of numerous Café-au-lait macules, cutaneous and plexiform neurofibromas, freckling of inguinal or axillary region, optic glioma, Lisch nodules and osseous lesions. Cherubism is a rare genetic syndrome described by progressive swelling of the lower and/or upper jaw due to replacement of bone by fibrous connective tissue. Patients are reported in the literature with NF1 and cherubism-like phenotype due to the NF1 osseous lesions in the jaws. The purpose of this case report is the description of a young male genetically diagnosed with both NF1 and cherubism.
Methods and results
A 9 years and six month old patient with clinical findings of NF1 and cherubism in whom both diseases were genetically confirmed, is presented. The patient was evaluated by a pediatrician, a pediatric endocrinologist, an ophthalmologist, and an oral and maxillofacial surgeon. A laboratory and hormonal screening, a histological examination, a chest X-ray, a magnetic resonance imaging (MRI) of the orbit and a digital panoramic radiography were performed. Genetic testing applying Whole Exome Sequencing was conducted.
Conclusions
A novel and an already reported pathogenic variants were detected in NF1 and SH3BP2 genes, respectively. This is the first described patient with coexistence of NF1 and cherubism. The contribution of Next Generation Sequencing (NGS) in gene variant identification as well as the importance of close collaboration between laboratory scientists and clinicians, is highlighted. Both are essential for optimizing the diagnostic approach of patients with a complex phenotype.
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152(2):327 – 32. https://doi.org/10.1002/ajmg.a.33139. PMID: 20082463
2. Luna EB, Janini ME, Lima F, Pontes RR, Guedes FR, Geller M, da Silva LE, Motta AT, Cunha KS (2018) Craniomaxillofacial morphology alterations in children, adolescents and adults with neurofibromatosis 1: a cone beam computed tomography analysis of a Brazilian sample. Med Oral Patol Oral Cir Bucal 23(2):e168–e179. https://doi.org/10.4317/medoral.22155. PMID: 29476678; PMCID: PMC5911357
3. Friedman JM, Neurofibromatosis (1998) 1. Oct 2 [Updated 2022 Apr 21]. In: Adam MP, Feldman J, Mirzaa GM, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1109/
4. Kannu P, Baskin B, Bowdin SC (2007) Feb 26 [Updated 2018 Nov 21]. In: Adam MP, Feldman J, Mirzaa GM, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1137/
5. Friedrich RE, Zustin J, Luebke AM, Rosenbaum T, Gosau M, Hagel C, Kohlrusch FK, Wieland I, Zenker M Neurofibromatosis type 1 with cherubism-like phenotype, multiple osteolytic bone lesions of lower extremities, and Alagille-syndrome: Case Report with Literature Survey. In Vivo 2021 May-Jun 35(3):1711–1736. https://doi.org/10.21873/invivo.12431. PMID: 33910856; PMCID: PMC8193341.